SAN FRANCISCO and SUZHOU, China, May 12, 2026
Innovent Biologics announced that it will present multiple clinical and preclinical advances from its rapidly expanding obesity and metabolic disease pipeline at the 2026 American Diabetes Association (ADA) Scientific Sessions, taking place in New Orleans from June 5–8, 2026. The presentations will feature extensive new data for mazdutide, the company’s investigational GCG/GLP-1 dual receptor agonist, alongside several next-generation obesity therapies including oral GLP-1 small molecules, amylin analogs, and RNA-based metabolic programs. Innovent stated that the ADA 2026 presentations reinforce the company’s ambition to establish itself as a major innovator in the global obesity therapeutics market, one of the fastest-growing sectors in the pharmaceutical industry. The latest findings highlight advances in weight reduction, glycemic control, metabolic improvement, liver disease management, and durable obesity treatment strategies targeting both adult and adolescent patient populations.
Mazdutide Strengthens Position in Obesity and Diabetes Care
A major focus of Innovent’s ADA 2026 presentations will center on mazdutide, an investigational dual glucagon receptor (GCGR) and GLP-1 receptor agonist designed to deliver enhanced weight loss and metabolic benefits beyond traditional GLP-1 therapies. One of the most anticipated oral presentations will feature results from the Phase 3b DREAMS-3 trial, which directly compared mazdutide against semaglutide in Chinese adults with type 2 diabetes and obesity. Additional data from the Phase 3 GLORY-2 trial will evaluate the efficacy and safety of higher-dose 9 mg mazdutide in adults with obesity, while another oral presentation will examine safety, tolerability, and pharmacokinetics in adolescents with obesity through a Phase 1b clinical study.
Innovent stated that the combined datasets demonstrate the broad therapeutic potential of mazdutide across multiple obesity-related indications and age groups. The company believes the therapy’s dual agonist mechanism may provide differentiated clinical advantages in terms of weight reduction, glucose control, metabolic regulation, and energy expenditure compared with conventional GLP-1 monotherapies. The obesity therapeutics market has become one of the most competitive areas in biopharmaceutical development following the commercial success of GLP-1 drugs such as Wegovy and Ozempic, prompting pharmaceutical companies worldwide to pursue next-generation combination therapies capable of delivering improved efficacy and tolerability.
Beyond obesity and diabetes management, Innovent will also present investigator-initiated studies evaluating mazdutide’s potential impact on metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and metabolic dysfunction-associated fatty liver disease (MAFLD). According to the company, preclinical findings suggest dual GLP-1R/GCGR activation may improve hepatic metabolism and reduce inflammatory liver damage through modulation of hepatocyte and hepatic stellate cell interactions. These findings are especially important as obesity-related liver diseases continue rising globally alongside increasing rates of diabetes and metabolic syndrome.
Innovent Expands Next-Generation Metabolic Pipeline
Advertisement
In addition to mazdutide, Innovent will showcase several emerging obesity programs designed to address key limitations associated with current weight-loss therapies. The company’s next-generation pipeline includes IBI3032, an oral daily nonpeptide GLP-1 receptor agonist currently advancing through Phase 1 clinical trials, and IBI3042, a novel oral once-weekly GLP-1 small molecule developed to improve dosing convenience and long-term treatment adherence. Innovent believes oral GLP-1 therapies may significantly expand patient accessibility by eliminating the need for injectable administration, a major barrier for some obesity and diabetes patients.
The company will also present preclinical findings for IBI3040, a novel amylin analog that demonstrated superior weight reduction in experimental models, and IBI3046, an investigational INHBE-targeting siRNA therapy designed to enable durable and high-quality weight control. Innovent stated that these programs were specifically developed to address critical unmet needs in obesity care, including muscle preservation, long-term weight maintenance, improved tolerability, and management of obesity-related comorbidities. Industry analysts believe next-generation combination approaches involving GLP-1 agonists, amylin analogs, and RNA-based therapies may represent the future direction of obesity treatment as companies compete to improve clinical outcomes while minimizing side effects.
Innovent Strengthens Global Metabolic Disease Strategy
The broad ADA 2026 data package reflects Innovent’s larger strategy to expand beyond oncology and establish a significant presence within the global metabolic disease therapeutics market. Founded in 2011, Innovent has rapidly evolved into one of China’s leading biopharmaceutical companies, with approved products spanning oncology, autoimmune disease, cardiovascular disorders, ophthalmology, and metabolic medicine. The company currently markets 18 products and maintains partnerships with major pharmaceutical organizations including Eli Lilly, Roche, Takeda, and Sanofi.
Innovent executives stated that the ADA Scientific Sessions presentations represent an important milestone in building a globally competitive obesity and metabolic disease franchise supported by differentiated mechanisms, flexible dosing platforms, and next-generation therapeutic technologies. As obesity prevalence continues increasing worldwide and demand grows for more effective long-term weight management solutions, Innovent aims to position its expanding metabolic pipeline among the leading innovation platforms competing in the rapidly evolving obesity therapeutics sector.
Source: Innovent Biologics press release
